Navigation Links
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Date:2/27/2009

PALO ALTO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today advised its stockholders to take no action at this time in response to Astellas Pharma Inc.'s announcement that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced an unsolicited tender offer for all outstanding common shares of CV Therapeutics at a price of $16.00 per share in cash.

CV Therapeutics' board of directors, in consultation with its independent financial and legal advisors, intends to advise stockholders of its formal position regarding the offer within 10 business days by filing a solicitation/recommendation statement on Schedule 14D-9 with the Securities and Exchange Commission and made available to stockholders.

Barclays Capital and Goldman Sachs are serving as financial advisors, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Additional Information

Stockholders of CV Therapeutics are advised to read CV Therapeutics' Schedule 14D-9 statement, when it becomes available, regarding the tender offer, because it will contain important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from MacKenzie Partners, Inc., which is assisting the company, by calling 800-322-2885 toll free or by calling 212-929-5500 or by emailing cvtx@mackenziepartners.com.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. ... Graph Database technology has been recognized As “ Best in Semantic Web Technology ... , “At Corporate America, it’s our priority to showcase prominent professionals who are ...
(Date:2/3/2016)... LONDON , Feb. 3, 2016  With ... current patent cliff that is underway, therapies such ... vaccines for a whole host of indications are ... to aid in the development and production of ... yields, poor quality and high costs, novel approaches ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... validating a series of potential targets (epitopes) specific to misfolded, propagating strains of ... to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from the ...
(Date:2/3/2016)... Buffalo, NY (PRWEB) , ... February 03, 2016 ... ... several new products to aid in the rapid development and ongoing quality control ... the Zika Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and ...
Breaking Biology Technology:
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):